Compensated vs Decompensated Cirrhosis: Clinical Differences and Antiviral Therapy Selection
For patients with decompensated cirrhosis (Child-Pugh B or C), sofosbuvir/velpatasvir with weight-based ribavirin for 12 weeks is the treatment of choice, and protease inhibitor-containing regimens are absolutely contraindicated due to substantially higher drug exposure and risk of toxicity. 1
Clinical Distinctions Between Compensated and Decompensated Cirrhosis
Compensated cirrhosis (Child-Pugh A) represents preserved liver function without overt clinical complications. These patients remain asymptomatic and have not experienced ascites, variceal bleeding, hepatic encephalopathy, or jaundice 2.
Decompensated cirrhosis (Child-Pugh B or C) is marked by the development of these clinical complications, representing a critical prognostic watershed. The median survival drops dramatically from 115 months in compensated patients to 55 months in decompensated patients 3. The 5-year survival rate for decompensated cirrhosis is only 14-35% compared to 84% in compensated disease 4, 5.
Critical Treatment Differences Based on Cirrhosis Stage
For Compensated Cirrhosis (Child-Pugh A):
Multiple treatment options are available including:
- Sofosbuvir/velpatasvir for 12 weeks (all genotypes)
- Sofosbuvir/velpatasvir/voxilaprevir for 12 weeks
- Glecaprevir/pibrentasvir for 16 weeks
- Protease inhibitors are permitted in this population 1
For Decompensated Cirrhosis (Child-Pugh B or C):
Treatment options are severely restricted due to safety concerns:
Recommended regimen:
- Sofosbuvir/velpatasvir with weight-based ribavirin (1,000 mg if <75 kg; 1,200 mg if ≥75 kg) for 12 weeks 1
- Ribavirin can be started at 600 mg daily and titrated based on tolerance 6, 7
Alternative for ribavirin-intolerant patients:
- Sofosbuvir/velpatasvir for 24 weeks without ribavirin 6
The Protease Inhibitor Contraindication: A Critical Safety Issue
This is the most important treatment distinction. Protease inhibitors (including glecaprevir, voxilaprevir, paritaprevir, grazoprevir, and asunaprevir) are absolutely contraindicated in decompensated cirrhosis because drug concentrations increase substantially, leading to hepatic failure and mortality 1, 7. This contraindication extends to patients with compensated (Child-Pugh A) cirrhosis who have had prior episodes of decompensation 1.
Evidence from ASTRAL-4: Genotype-Specific Considerations
The ASTRAL-4 study provides critical data for decompensated patients 1:
SVR12 rates with sofosbuvir/velpatasvir + ribavirin for 12 weeks:
- Genotype 1a: 94%
- Genotype 1b: 100%
- Genotype 2: 100%
- Genotype 3: 85% (notably lower, requiring special attention)
- Genotype 4: 100%
Genotype 3 represents the highest risk group in decompensated cirrhosis, with only 50% SVR when ribavirin is omitted 1. This underscores the critical importance of ribavirin in this population.
Management Location and Monitoring Requirements
Patients with decompensated cirrhosis must be treated in experienced centers with easy access to liver transplantation 1, 7. Close monitoring is required with the possibility of stopping therapy if worsening decompensation occurs during treatment 1.
Potential for Clinical Improvement
Achieving SVR in decompensated patients leads to:
- Significant improvements in bilirubin, albumin, and INR values
- Reduction in MELD scores
- 51% of patients with baseline MELD <15 showed improved MELD scores at week 12 post-treatment
- 81% of patients with baseline MELD ≥15 showed improvement 1
However, improvement is unlikely in patients with baseline MELD scores ≥20 1, 7. Approximately one-third to one-half of decompensated patients achieve functional improvement sufficient for potential delisting from transplant waiting lists 1, 6.
Common Pitfalls to Avoid
- Never use protease inhibitors in decompensated patients - this is the single most critical error to avoid
- Do not delay treatment - patients with decompensated cirrhosis should be treated urgently 6
- Do not omit ribavirin in genotype 3 - SVR rates drop from 85% to 50% 1
- Do not assume all decompensated patients will improve - those with MELD ≥20 or severe decompensation may not benefit sufficiently 1, 7